Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

6.3K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.3K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.4K
Barrett Esophagus-II: Clinical Manifestations and Management01:21

Barrett Esophagus-II: Clinical Manifestations and Management

75
Individuals with Barrett's esophagus are often asymptomatic, but they may experience symptoms commonly associated with GERD, such as heartburn and acid regurgitation. Additional symptoms can include difficulty swallowing, chest pain, unintentional weight loss, blood in the stool (which may appear black, tarry, or bloody), and episodes of vomiting.
To diagnose Barrett's esophagus, healthcare providers often recommend an endoscopy for those showing symptoms of acid reflux. The procedure...
75

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pattern of lymph node spread in gastric cancer: Western multicenter retrospective study.

BJS open·2026
Same author

Management of iatrogenic esophageal perforations: a systematic review of non-surgical causes.

Surgical endoscopy·2026
Same author

Advances in Non-Alcoholic Fatty Liver Disease: Pathophysiology, Diagnosis, and Emerging Therapies.

Life (Basel, Switzerland)·2026
Same author

Impact of Gut Microbiota on the Clinical Course and Treatment Outcomes of Colorectal Cancer-A Systematic Review.

Medicina (Kaunas, Lithuania)·2026
Same author

Tumor Deposits in Gastric Cancer: A Systematic Review of the Literature With Meta-Analysis on Prevalence and Prognostic Implications.

Annals of surgery open : perspectives of surgical history, education, and clinical approaches·2026
Same author

Burnout and Insomnia Among Greek Physicians Affiliated with the Athens Medical Association After the Acute Phase of the COVID-19 Pandemic: Prevalence and Contributing Factors.

Epidemiologia (Basel, Switzerland)·2026

Related Experiment Video

Updated: May 10, 2025

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT
10:28

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT

Published on: January 22, 2018

10.7K

The Role of Visfatin in Gastric and Esophageal Cancer: From Biomarker to Therapeutic Target.

Adam Mylonakis1, Alexandros Kozadinos1, Maximos Frountzas2

  • 1First Department of Surgery, Laikon General Hospital, National and Kapodistrian University of Athens, 11527 Athens, Greece.

Cancers
|April 26, 2025
PubMed
Summary
This summary is machine-generated.

Visfatin (nicotinamide phosphoribosyltransferase) shows potential as a biomarker and therapeutic target for gastric and esophageal cancers. Targeting visfatin may improve treatment outcomes, but further research is needed to overcome toxicity and refine therapies.

Keywords:
biomarkersesophageal cancergastric cancertherapeutic targetsupper gastrointestinal cancer

More Related Videos

Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies
07:47

Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies

Published on: September 15, 2023

1.4K
Development of Compendium for Esophageal Squamous Cell Carcinoma
03:36

Development of Compendium for Esophageal Squamous Cell Carcinoma

Published on: April 12, 2024

341

Related Experiment Videos

Last Updated: May 10, 2025

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT
10:28

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT

Published on: January 22, 2018

10.7K
Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies
07:47

Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies

Published on: September 15, 2023

1.4K
Development of Compendium for Esophageal Squamous Cell Carcinoma
03:36

Development of Compendium for Esophageal Squamous Cell Carcinoma

Published on: April 12, 2024

341

Area of Science:

  • Biochemistry
  • Oncology
  • Metabolic pathways

Background:

  • Gastric and esophageal cancers are highly lethal malignancies with a need for better biomarkers and therapies.
  • Visfatin (nicotinamide phosphoribosyltransferase/NAMPT) is an enzyme and adipokine involved in cancer progression, but its role in upper GI cancers is unclear.
  • This review examines visfatin's properties, role in upper GI cancer pathogenesis, and therapeutic potential.

Purpose of the Study:

  • To explore the biochemical properties of visfatin.
  • To elucidate visfatin's role in the pathogenesis of gastric and esophageal cancers.
  • To assess visfatin's implications as a potential therapeutic target in upper GI malignancies.

Main Methods:

  • Comprehensive literature review on visfatin in gastric and esophageal cancer.
  • Analysis of studies on visfatin expression, prognostic significance, and therapeutic targeting.
  • Review of preclinical and clinical studies on visfatin inhibitors.

Main Results:

  • Visfatin promotes tumor progression via angiogenesis, epithelial-mesenchymal transition (EMT), and immune suppression.
  • Elevated visfatin correlates with advanced stage, poor chemotherapy response, and worse prognosis in upper GI cancers.
  • Visfatin inhibitors like FK866 show preclinical promise in reducing tumor growth and improving chemoresistance, but clinical use is limited by toxicity.

Conclusions:

  • Visfatin is a promising biomarker and therapeutic target for gastric and esophageal cancers.
  • Further research is essential to clarify visfatin's mechanisms and validate its prognostic value.
  • Optimizing visfatin-targeted therapies is crucial, especially for obesity-associated and chemoresistant cancers.